Glucagon-like insulinotropic peptides, compositions and methods

Details Glucagon-like insulinotropic peptides, compositions and methods Glucagon-like insulinotropic peptides, compositions and methods

2007-06-19

2007-06-19

Chism, B. Dell (Department: 1654)

Chemistry: natural resins or derivatives; peptides or proteins;

Peptides of 3 to 100 amino acid residues

Glucagon; related peptides

C530S324000, C514S012200

Reexamination Certificate

active

10769080

ABSTRACT:
The present invention provides novel complexes consisting of certain GLP-1 molecules associated with a divalent metal cation that is capable of co-precipitating with a GLP-1 molecule. Pharmaceutical compositions and methods of using such complexes for enhancing the expression of insulin in B-type islet cells is claimed, as is a method for treating maturity onset diabetes mellitus in mammals, particularly humans.

REFERENCES:
patent: 4347374 (1982-08-01), Kollonitsch et al.
patent: 5118666 (1992-06-01), Habener
patent: 5120712 (1992-06-01), Habener
patent: 5545618 (1996-08-01), Buckley et al.
patent: 5705483 (1998-01-01), Galloway et al.
patent: 5977071 (1999-11-01), Galloway et al.
patent: 6133235 (2000-10-01), Galloway et al.
patent: 6284727 (2001-09-01), Kim et al.
patent: 6388053 (2002-05-01), Galloway et al.
patent: 6410513 (2002-06-01), Galloway et al.
patent: 6703365 (2004-03-01), Galloway et al.
patent: 619322 (1994-02-01), None
patent: 0 587 255 (1994-03-01), None
patent: 619322 (1996-03-01), None
patent: WO 87/06941 (1987-11-01), None
patent: WO 91/11457 (1991-08-01), None
patent: WO 92/18531 (1992-10-01), None
patent: WO 93/18786 (1993-09-01), None
patent: WO 95/05848 (1995-03-01), None
patent: WO 93/25579 (1995-12-01), None
U.S. Appl. No. 10/125,255, Galloway, et al.
Komatsu, R., et al., Diabetes, 38:902-905 (1989).
Orskov, C., et al.,J. Biol. Chem., 264(22):12826-12829 (1989).
Majsov, S.,Int. J. Peptide Protein Res., 40:333-343 (1989).
Holz, G.G., et al.,Nature, 361:362-365 (1993).
Orskov, C.,Diabetologia, 35:701-711 (1992).
Mentlein, R., et al.,Eur. J. Biochem., 214:829-835 (1993).
Handbook of Experimental Pharmacology, Springer-Verlag, Hasselblatt, et al., (Eds.), 32(2):729-777 (1975).
Nauck, M.A., et al.,J. Clin. Invest., 91:301-307 (1993).
Nauck, M.A., et al.,Diabetologia, 36:741-744 (1993).
Gutniak, M., et al.,N. E. J. Med., 326(20):1316-1322 (1992).
Thorens, B., et al., Diabetes, 42:1219-1225 (1993).
Levine-Pinto, H., et al.,Biochem. Biophys. Res. Commun., 103(4):1121-1130 (1981).
Owa, T., et al.,Chem. Letters, 873-874 (1988).
Altman, J., et al.,Synthetic Commun., 19(11&12):2069-2076 (1989).
O'Donnell, J.J., et al.,Synthetic Commun., 19(7&8):1157-1165 (1989).
Galloway, J.A.,Diabetes Care, 13:1209-1239 (1990).
Galloway, J.A., et al.,Clin. Therap., 12:460-472 (1990).
Suzuki, S., et al.,Endocrinology, 125:3109-3114 (1990).
Ananthanancayanan, V.V., et al.,Mol. Biol. Cell(Supp) 3:250A (1992).
Epand, R.M.,Mol. Pharmacol., 22:105-108 (1982).
Pridal, L., et al., “Absorption of Glucagon-Like Peptide-1 Can Be Protracted by Zinc or Protamine”,International Journal of Pharmaceuticals, 136:53-59 (1996).

Affiliated with

Also associated with

Rating

Glucagon-like insulinotropic peptides, compositions and methods does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Glucagon-like insulinotropic peptides, compositions and methods, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Glucagon-like insulinotropic peptides, compositions and methods will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3854811